为什么NSAIDS的直肠路径有利于预防ERCP后胰腺炎?
Gayathri Swaminathan1, Yu-Chu Lin1, Jianbo Ni2
1Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Stanford University, School of Medicine, Stanford, CA, USA.
概括
直肠非类固醇抗炎药物 (NSAIDs) 提供更好的保护后ERCP胰腺炎 (PEP) 由于持续的全身暴露,而不仅仅是胰腺水平. 这支持直肠NSAID用于持续PEP漏洞覆盖.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 药物输送系统 药物输送系统
背景情况:
- 急性胰腺炎是ERCP的常见并发症.
- 与其他途径相比,直肠NSAID显著降低ERCP后胰腺炎 (PEP) 的风险.
- 在直肠NSAIDs的优越疗效背后的机制尚未完全理解.
研究的目的:
- 为了研究通过直肠,静脉和胃肠道给药的迪克洛菲纳克的药理学特征.
- 为了在不同的施用方法中比较全身和组织 (胰腺) 药物水平.
- 阐明直肠NSAIDs在预防PEP方面的有效性的药理动力学基础.
主要方法:
- 一项使用C57BL/6J小鼠的临床前研究.
- 狄克洛菲纳克用临床相当剂量 (20.8 mg/kg) 通过直肠,静脉和口服途径进行.
- 血液和组织样本收集在不同的时间点进行药理动力学分析.
主要成果:
- 结肠直肠二甲显示出良好的全身生物可用性和持续的胰腺透.
- 胰腺对迪克洛芬雅克24小时的总暴露在直肠,静脉和口腔途径中是可比的.
- 通过直肠给药导致更高和更一致的全身暴露.
结论:
- 在预防PEP方面,直肠二二的疗效与其持续的全身暴露有关.
- 较高的绝对胰腺药物水平不仅仅解释了直肠路线的有效性.
- 直肠路由确保整个PEP易受影响期内全身和胰腺药物暴露.
相关概念视频
Endoscopic Procedures V: ERCP
60
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...
Patient...
60
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
328
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
328
Drugs for Treatment of Constipation-Predominant IBS
129
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
129
Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140
Additional Routes of Drug Administration
2.7K
Choosing the appropriate route of drug administration is significantly influenced by two key factors: the therapeutic objectives and the inherent properties of the drug being used.
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
2.7K


